Yifan Pharmaceutical Co., Ltd.

SZSE:002019 Stock Report

Market Cap: CN¥12.6b

Yifan Pharmaceutical Future Growth

Future criteria checks 4/6

Yifan Pharmaceutical is forecast to grow earnings and revenue by 68.6% and 17.4% per annum respectively. EPS is expected to grow by 68.5% per annum. Return on equity is forecast to be 8.4% in 3 years.

Key information

68.6%

Earnings growth rate

68.5%

EPS growth rate

Pharmaceuticals earnings growth19.5%
Revenue growth rate17.4%
Future return on equity8.4%
Analyst coverage

Low

Last updated20 Aug 2024

Recent future growth updates

Recent updates

These 4 Measures Indicate That Yifan Pharmaceutical (SZSE:002019) Is Using Debt Extensively

Jun 04
These 4 Measures Indicate That Yifan Pharmaceutical (SZSE:002019) Is Using Debt Extensively

Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Shares Leap 28% Yet They're Still Not Telling The Full Story

May 08
Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Shares Leap 28% Yet They're Still Not Telling The Full Story

A Piece Of The Puzzle Missing From Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price

Mar 01
A Piece Of The Puzzle Missing From Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price

Earnings and Revenue Growth Forecasts

SZSE:002019 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20267,377930N/A6993
12/31/20256,413774N/A9523
12/31/20245,367551N/A-923
6/30/20244,756-407-166339N/A
3/31/20244,456-47011527N/A
12/31/20234,068-551-156349N/A
9/30/20234,038135-128456N/A
6/30/20234,011139-126442N/A
3/31/20233,869135-5520N/A
1/1/20233,837191-70472N/A
9/30/20223,740191-146247N/A
6/30/20223,801226-228259N/A
3/31/20224,115267-419106N/A
1/1/20224,409278-271301N/A
9/30/20214,656348-389348N/A
6/30/20214,967463-178587N/A
3/31/20215,2767773131,051N/A
12/31/20205,4009683931,109N/A
9/30/20205,5331,0737561,644N/A
6/30/20205,4801,1367541,573N/A
3/31/20205,3761,0802671,190N/A
12/31/20195,18790371937N/A
9/30/20194,994769-181641N/A
6/30/20194,824683-189592N/A
3/31/20194,51555943732N/A
12/31/20184,6327374421,171N/A
9/30/20184,7421,1407371,394N/A
6/30/20184,8421,3648211,445N/A
3/31/20184,7601,431N/A1,425N/A
12/31/20174,3731,305N/A1,133N/A
9/30/20173,9001,045N/A1,033N/A
6/30/20173,630821N/A1,085N/A
3/31/20173,548768N/A954N/A
12/31/20163,505705N/A856N/A
9/30/20163,282604N/A586N/A
6/30/20162,948554N/A468N/A
3/31/20162,664413N/A341N/A
12/31/20152,435361N/A402N/A
9/30/20152,446420N/A343N/A
6/30/20152,237327N/A147N/A
3/31/20151,930280N/A142N/A
12/31/20141,685238N/A140N/A
9/30/20141,414148N/A102N/A
6/30/20141,327146N/A95N/A
3/31/20141,331155N/A86N/A
12/31/20131,158118N/A34N/A
9/30/201396870N/A42N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 002019 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).

Earnings vs Market: 002019 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 002019 is expected to become profitable in the next 3 years.

Revenue vs Market: 002019's revenue (17.4% per year) is forecast to grow faster than the CN market (13.3% per year).

High Growth Revenue: 002019's revenue (17.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 002019's Return on Equity is forecast to be low in 3 years time (8.4%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y